United States. Securities and Exchange Commission
Ocugen, Inc., a biopharmaceutical company, has submitted a U.S. Securities and Exchange Commission (SEC) filing, specifically Form D, on May 7, 2020. The filing notifications the sale of securities by the company, which is required under Regulation D or Section 4(6) exemptions from the registration provisions of the
Pharmaceutical industry
Peregrine Pharmaceuticals, Inc. has announced the receipt of a grant from the U.S. Department of Defense to study the use of vascular targeting antibodies in combination with chemotherapy agents for the treatment of prostate cancer. The grant, totaling $582,988, will be used to support pre-clinical studies at the
Pharmaceutical industry
The U.S. Food and Drug Administration has approved Tarceva (erlotinib) in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. Tarceva is the first drug to show a significant improvement in overall survival when added to gemcitabine chemotherapy as
Pharmaceutical industry
Laurie Garrett, who runs the Global Health Program at the Council on Foreign Relations, notes that people are trying to do the right thing but nobody knows what the right thing is. Governments are spending billions of dollars to buy medicines and vaccines to prepare for a possible human bird
Pharmaceutical industry
Initial data from a phase II trial of AS1404 in lung cancer patients indicate a higher frequency of tumour responses and a lower frequency of progressive disease in patients receiving AS1404 in addition to chemotherapy compared to those receiving chemotherapy alone. The trial, which is ongoing, has enrolled 71 patients,
Pharmaceutical industry
Antisoma, a biopharmaceutical company developing novel products for cancer treatment, has announced that it has reached the patient recruitment target for its phase II trial of AS1404 in non-small cell lung cancer. This milestone keeps the company on track to report the first efficacy data from the trial during the
Pharmaceutical industry
Federal regulators have approved a third flu vaccine for distribution to Americans, in a bid to avoid a repeat of last year's shortage. The Food and Drug Administration (FDA) has given the green light to Fluarix, made by GlaxoSmithKline in Germany, which will add at least 8 million
Biotechnology industries
Seattle Genetics, Inc. has licensed its proprietary antibody-drug conjugate (ADC) technology to PSMA Development Company LLC, a joint venture between Progenics Pharmaceuticals, Inc. and Cytogen Corporation. This multi-year agreement provides PDC with access to the ADC technology for use with antibodies targeting prostate-specific membrane antigen (PSMA), a protein highly expressed
Biotechnology industries
Researchers at Generex Biotechnology's subsidiary, Antigen Express, Inc., have made significant strides in developing a novel approach to controlling both fatal and disabling allergic reactions. A research collaboration agreement with Stallergenes, SA, a major European firm in immunological treatments for allergy and asthma, aims to design and test
Pharmaceutical industry
The biopharmaceutical company Antisoma has started a phase II trial of its vascular disrupting agent AS1404 in recurrent ovarian cancer, marking the third and final trial in a series evaluating AS1404 in combination with chemotherapy drugs. The trial, which will involve around 70 patients from Europe, Australia, and New Zealand,
Pharmaceutical industry
Ono Pharmaceutical Co., Ltd. and Medarex, Inc. have entered into a collaborative research agreement to develop a fully human antiPD-1 antibody for the potential treatment of cancer. The companies have already started working on generating product candidates and expect to begin clinical studies within 12 to 24 months. Under the
Biotechnology industries
Vitro Diagnostics, Inc. has announced the filing of a new patent application with the United States Patent and Trademark Office, describing a method for generating beta islets from stem cells. The company's breakthrough discovery enables the creation of immortal cell lines that can be induced to form beta
